Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRC HEALTHNRCIA/B · Entity 5534 | Director | May 09, 2017 | May 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRC HEALTH
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.35 · Expires 2027-05-09 | Direct | 36,000 |
Reported balance
After 2017-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-09 · Grant · Acquired 36,000 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.47 · Expires 2027-05-09 | Direct | 6,000 |
Reported balance
After 2017-05-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-09 · Grant · Acquired 6,000 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.49 · Expires 2018-05-02 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2019-05-08 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2020-05-07 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.73 · Expires 2021-05-06 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.81 · Expires 2022-05-11 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.89 · Expires 2023-05-09 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2024-05-08 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.21 · Expires 2025-05-07 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2026-05-11 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 36,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2018-05-02 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.06 · Expires 2019-05-08 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.80 · Expires 2020-05-07 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.98 · Expires 2021-05-06 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.10 · Expires 2022-05-11 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.72 · Expires 2023-05-09 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.91 · Expires 2024-05-08 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.50 · Expires 2025-05-07 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 6,000 |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.78 · Expires 2026-05-11 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 6,000 |
| Class A Common StockSEC Table I · non-derivative | Direct | 60,671 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,671 |
| Class B Common StockSEC Table I · non-derivative | Direct | 10,263 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,263 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2017 Filed May 11, 2017 16:31 UTC | NRC HEALTH NRCIA/B · Entity 5534 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $44.47 | $0.00 |
DisclosureSEC source: 0001140361-17-019566 · doc1.xml · derivative · entry 4 WARDEN GAIL L · CIK 0001200073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Class B Common Stock · 6,000 shares Expires 2027-05-09 Read SEC document |
| May 09, 2017 Filed May 11, 2017 16:31 UTC | NRC HEALTH NRCIA/B · Entity 5534 | GrantDirector Stock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001140361-17-019566 · doc1.xml · derivative · entry 3 WARDEN GAIL L · CIK 0001200073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Class A Common Stock · 36,000 shares Expires 2027-05-09 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.